Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease
Identifieur interne : 000E15 ( Main/Exploration ); précédent : 000E14; suivant : 000E16Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease
Auteurs : Masaki Wakamatsu [Japon] ; Shingo Iwata [Japon] ; Takeo Funakoshi [Japon] ; Makoto Yoshimoto [Japon]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2008-02-15.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) is characterized by loss of nigral dopaminergic (DAergic) neurons and presence of Lewy bodies, whose major component is α‐synuclein. We had previously generated transgenic mice termed Syn130m that express truncated human α‐synuclein (amino acid residues 1–130) in DAergic neurons. Syn130m mice showed significant loss of DAergic neurons in the substantia nigra pars compacta. Subsequently, the striatal DA level and spontaneous locomotor activity of the mice were decreased significantly. In the present study, we investigated behavioral responses of Syn130m mice to L‐DOPA and DA receptor agonists. Administration of L‐DOPA dose dependently ameliorated the reduction of spontaneous locomotor activity of Syn130m mice. Similarly, D2 agonists, quinpirole and talipexole, and a D1/D2 agonist, pergolide, were effective against the reduction. Syn130m mice also showed significant reduction in exploratory behavior compared with non‐Tg littermates when they were placed in a novel environment, but this abnormality was ameliorated by treatment with pergolide. These results strongly suggest that the behavioral abnormalities of Syn130m mice were caused by low striatal DA content. On the other hand, the expression of postsynaptic D2‐like receptors (DRD2) in the striatum was not increased in Syn130m mice, although the low striatal DA level is known to induce compensatory expression of DRD2. Because the abnormalities could be rectified by treatment with DA receptor agonists, it is likely that Syn130m mice provide a useful tool to explore therapeutic possibilities for PD as a new animal model of the disease. © 2007 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.21513
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease</title><author><name sortKey="Wakamatsu, Masaki" sort="Wakamatsu, Masaki" uniqKey="Wakamatsu M" first="Masaki" last="Wakamatsu">Masaki Wakamatsu</name></author><author><name sortKey="Iwata, Shingo" sort="Iwata, Shingo" uniqKey="Iwata S" first="Shingo" last="Iwata">Shingo Iwata</name></author><author><name sortKey="Funakoshi, Takeo" sort="Funakoshi, Takeo" uniqKey="Funakoshi T" first="Takeo" last="Funakoshi">Takeo Funakoshi</name></author><author><name sortKey="Yoshimoto, Makoto" sort="Yoshimoto, Makoto" uniqKey="Yoshimoto M" first="Makoto" last="Yoshimoto">Makoto Yoshimoto</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:929D3A05B7BCCEFE3C10004E50DE3E6C7FC3366D</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/jnr.21513</idno><idno type="url">https://api.istex.fr/document/929D3A05B7BCCEFE3C10004E50DE3E6C7FC3366D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002056</idno><idno type="wicri:Area/Main/Curation">001D55</idno><idno type="wicri:Area/Main/Exploration">000E15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease</title><author><name sortKey="Wakamatsu, Masaki" sort="Wakamatsu, Masaki" uniqKey="Wakamatsu M" first="Masaki" last="Wakamatsu">Masaki Wakamatsu</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author><author><name sortKey="Iwata, Shingo" sort="Iwata, Shingo" uniqKey="Iwata S" first="Shingo" last="Iwata">Shingo Iwata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author><author><name sortKey="Funakoshi, Takeo" sort="Funakoshi, Takeo" uniqKey="Funakoshi T" first="Takeo" last="Funakoshi">Takeo Funakoshi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author><author><name sortKey="Yoshimoto, Makoto" sort="Yoshimoto, Makoto" uniqKey="Yoshimoto M" first="Makoto" last="Yoshimoto">Makoto Yoshimoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-02-15">2008-02-15</date><biblScope unit="volume">86</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="640">640</biblScope><biblScope unit="page" to="646">646</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">929D3A05B7BCCEFE3C10004E50DE3E6C7FC3366D</idno><idno type="DOI">10.1002/jnr.21513</idno><idno type="ArticleID">JNR21513</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐DOPA</term><term>Parkinson's disease</term><term>dopaminergic neuron</term><term>locomotor activity</term><term>pergolide</term><term>tali‐pexole</term><term>transgenic mouse</term><term>α‐synuclein</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is characterized by loss of nigral dopaminergic (DAergic) neurons and presence of Lewy bodies, whose major component is α‐synuclein. We had previously generated transgenic mice termed Syn130m that express truncated human α‐synuclein (amino acid residues 1–130) in DAergic neurons. Syn130m mice showed significant loss of DAergic neurons in the substantia nigra pars compacta. Subsequently, the striatal DA level and spontaneous locomotor activity of the mice were decreased significantly. In the present study, we investigated behavioral responses of Syn130m mice to L‐DOPA and DA receptor agonists. Administration of L‐DOPA dose dependently ameliorated the reduction of spontaneous locomotor activity of Syn130m mice. Similarly, D2 agonists, quinpirole and talipexole, and a D1/D2 agonist, pergolide, were effective against the reduction. Syn130m mice also showed significant reduction in exploratory behavior compared with non‐Tg littermates when they were placed in a novel environment, but this abnormality was ameliorated by treatment with pergolide. These results strongly suggest that the behavioral abnormalities of Syn130m mice were caused by low striatal DA content. On the other hand, the expression of postsynaptic D2‐like receptors (DRD2) in the striatum was not increased in Syn130m mice, although the low striatal DA level is known to induce compensatory expression of DRD2. Because the abnormalities could be rectified by treatment with DA receptor agonists, it is likely that Syn130m mice provide a useful tool to explore therapeutic possibilities for PD as a new animal model of the disease. © 2007 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Wakamatsu, Masaki" sort="Wakamatsu, Masaki" uniqKey="Wakamatsu M" first="Masaki" last="Wakamatsu">Masaki Wakamatsu</name></noRegion><name sortKey="Funakoshi, Takeo" sort="Funakoshi, Takeo" uniqKey="Funakoshi T" first="Takeo" last="Funakoshi">Takeo Funakoshi</name><name sortKey="Iwata, Shingo" sort="Iwata, Shingo" uniqKey="Iwata S" first="Shingo" last="Iwata">Shingo Iwata</name><name sortKey="Yoshimoto, Makoto" sort="Yoshimoto, Makoto" uniqKey="Yoshimoto M" first="Makoto" last="Yoshimoto">Makoto Yoshimoto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:929D3A05B7BCCEFE3C10004E50DE3E6C7FC3366D
|texte= Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |